Abstracts tagged "immunology"

Abstract Number: 1747 • ACR Convergence 2022
Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis
Cliff Rims¹, Virginia Muir¹, Anne Hocking¹, Sylvia Posso¹, Heather Bukiri², Jeffrey Carlin³, Bernard Ng⁴, Peter Linsley¹, Eddie James⁵ and Jane Buckner⁵, ¹Benaroya Research Institute, Seattle, WA, ²University of California Los Angeles, Los Angeles, CA, ³Virginia Mason Medical Center, Seattle, WA, ⁴VA Puget Sound HCS, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: In Rheumatoid arthritis (RA) citrullinated antigen reactive T cells are key drivers of disease, but knowledge about their relative number and phenotype remains limited.…
Abstract Number: 2267 • ACR Convergence 2022
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Thomas Vazquez¹, Nilesh Kodali¹, DeAnna Diaz², Jay Patel³, Emily Keyes², Grant Sprow², Meena Sharma¹, Mariko Ogawa-Momohara², Madison Grinnell², Josh Dan² and Victoria Werth², ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN
Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 0667 • ACR Convergence 2022
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: First-line treatment for cutaneous lupus erythematosus involves the use of antimalarials. Treatment response is highly variable with some patients responding well to hydroxychloroquine (HCQ),…
Abstract Number: 1059 • ACR Convergence 2022
Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
Alexandru Garaiman¹, Farhad Nooralahzadeh², Carina Mihai¹, Nikitas Gkikopoulos¹, Nicolas Perez Gonzalez², Mike Becker¹, Oliver Distler¹, Michael Krauthammer³ and Britta Maurer⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Biomedical Informatics, University of Zurich, Zürich, Switzerland, ³Department of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland, ⁴Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland
Background/Purpose: An accurate assessment of nailfold capillaroscopy (NFC) images has great importance in the diagnosis and prognosis of systemic sclerosis (SSc). To overcome some of…
Abstract Number: 1687 • ACR Convergence 2022
A Core Inflammation Program Conserved Across Human and Murine Neutrophils
Nicolaj hackert¹, Felix Radtke¹, Tarik Exner¹, Carsten Müller-Tidow¹, Hanns-Martin Lorenz¹, Peter Nigrovic², Guido Wabnitz¹ and Ricardo Grieshaber-Bouyer¹, ¹Heidelberg University Hospital, Heidelberg, Germany, ²Boston Children's Hospital, Boston, MA
Background/Purpose: Neutrophils mediate a range of homeostatic and inflammatory processes and display substantial phenotypic and functional heterogeneity. While animal models enable important mechanistic discoveries, differences…
Abstract Number: 1749 • ACR Convergence 2022
Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis
Eddie James¹, Cliff Rims², Sylvia Posso², Jeffrey Carlin³, William Kwok², Shao-En Ong⁴ and Jane Buckner¹, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease in which citrullinated self-antigens are recognized by anti-citrullinated protein antibodies (ACPA) and T cells. ACPA are a…
Abstract Number: 0549 • ACR Convergence 2022
Efficacy and Safety of the SARS-CoV-2 Vaccine in Patients with Rheumatoid Arthritis
Esther Vicente-Rabaneda¹, María Torres², Miren Uriarte³, Patricia Quiroga-Colina³, Ainhoa Gutiérrez⁴, Ana Triguero⁵, Francisco Gutiérrez³, Noelia García³, Ana Romero-Robles³, Laura Cardeñoso⁴ and Santos Castañeda¹, ¹Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ²Medical student, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ⁴Division of Microbiology, Hospital Universitario de La Princesa, Madrid, Spain, ⁵Hospital Universitario La Princesa, Madrid, Spain
Background/Purpose: To describe the efficacy and safety of the SARS-CoV-2 vaccine in a series of patients with rheumatoid arthritis (RA).Methods: Retrospective observational study of RA…
Abstract Number: 0740 • ACR Convergence 2022
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study
Carl Allen¹, Shanmuganathan Chandrakasan², Michael Jordan³, Jennifer Leiding⁴, Abiola Oladapo⁵, Priti Pednekar⁶, Kelly Walkovich⁷ and John Yee⁸, ¹Baylor College of Medicine, Houston, TX, ²Emory University School of Medicine, Atlanta, GA, ³University of Cincinnati, Cincinnati, OH, ⁴Johns Hopkins University, Baltimore, MD, ⁵Swedish Orphan Biovitrum AB, Boston, MA, ⁶PRECISIONheor, Los Angeles, CA, ⁷University of Michigan Health, Ann Arbor, MI, ⁸Sobi - North America, Waltham, MA
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening, hyperinflammatory syndrome caused by overproduction of proinflammatory cytokines, e.g., interferon gamma (IFNγ). Secondary HLH (sHLH), a subtype…
Abstract Number: 1095 • ACR Convergence 2022
A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease
Bahram Razani¹, Jared Liu¹, Ryan Tobias¹, Sugandh Kumar¹, Zhi-Ming Huang¹, Wilson Liao², Barbara Malynn³ and Averil Ma³, ¹Dept. of Dermatology, UCSF, San Francisco, ²Dept. of Dermatology, San Francisco, ³Division of Gastroenterology, UCSF, San Francisco
Background/Purpose: A20 (Tnfaip3) levels are reduced in psoriatic plaques and polymorphisms in the TNFAIP3 gene locus are associated with increased risk for both psoriasis and psoriatic…
Abstract Number: 1698 • ACR Convergence 2022
LINE1 Reverse Transcriptase Inhibitors Abrogate Type 1 Interferon Responses
Daniel Rios¹, Nafeeza Hafeez¹, Brian Desrosiers¹, Shradha Rao¹, Jess Floro¹, Joelle Baddour¹, Nisha Perez², Greg Bisacchi², Oliver Saunders², Donna Romero¹, Menachem Fromer², Enrique Garcia-Rivera², Wilson McKerrow², Julie Behr², Bryan Thornlow², Dennis Zaller², David Proia² and Wenyan Miao², ¹Rome Therapeutics, Cambridge, MA, ²Rome Tx, Cambridge, MA
Background/Purpose: Transposable elements (TEs) are mobile DNA elements that can replicate and move from one position to another within the host genome. Through co-evolution, TEs…
Abstract Number: 1762 • ACR Convergence 2022
Stability of Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Other Autoimmune Biomarkers Among Clinical Patients Throughout the SARS-CoV-2 Pandemic and Vaccination Campaigns
Mark Rudolph, Rory Bloch, Anja Kammesheidt and Roberta Alexander, Exagen, Inc., Vista, CA
Background/Purpose: COVID-19 can cause autoantibody signatures in severely ill patients, and widespread emerging post-acute sequelae of SARS-CoV-2 (PASC) share many symptoms consistent with rheumatologic involvement…
Abstract Number: 0012 • ACR Convergence 2022
Role of Type L IFN Signaling on B Cell Pathogenicity in Early Sjögren’s Disease in Mouse Model
Merri-Grace Allred and Scott Lieberman, University of Iowa, Iowa City, IA
Background/Purpose: Sjogren's disease is a chronic autoimmune disease autoimmune disease characterized by foci of inflammation of the lacrimal and salivary glands. As disease progresses, B…
Abstract Number: 0558 • ACR Convergence 2022
Molecular Interplay Between Mammalian Target of Rapamycin (mTOR) and the YAP Pathway Mediates Rheumatoid Arthritis Synovial Fibroblast Activation
Brianne Barker¹, Megan Hanlon², Siobhan Wade¹, Douglas Veale³, Ursula Fearon¹ and Mary Canavan⁴, ¹Trinity College Dublin, Dublin, Ireland, ²Molecular Rheumatology, Dublin, Ireland, ³St. Vincent's University Hospital, Blackrock, Dublin, Ireland, ⁴Trinity College, Dublin, Ireland
Background/Purpose: mTOR is a metabolic master regulator of both innate and adaptive immunity, however its exact role in synovial fibroblasts is unknown. RA synovial fibroblasts…
Abstract Number: 0752 • ACR Convergence 2022
A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of Ebdarokimab in Patients with Moderate to Severe Plaque Psoriasis
Rui Chen¹, Yu Xia², Baiyong Li², Xiang Ni², Guoqin Wang², Cui Zhang², Benchao Chen², Li Wang² and Hongzhong Jin³, ¹Clinical Pharmacology Research Center, Peking Union Medical College Hospital, State Key Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Akeso Biopharma, Inc., Zhongshan, China, ³Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Disease, Beijing, China
Background/Purpose: Interleukin-12 (IL-12) and interleukin-23 (IL-23) are two essential cytokins involved in the immune-mediated inflammatory disorders of psoriasis. Anti-IL-12/IL-23 therapy has been developed for the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].